Goldman Sachs Group Inc. Upgrades Henry Schein Inc. (HSIC) to “Buy”
Henry Schein Inc. (NASDAQ:HSIC) was upgraded by investment analysts at Goldman Sachs Group Inc. from a “neutral” rating to a “buy” rating in a research report issued on Tuesday.
Several other research firms have also issued reports on HSIC. Zacks Investment Research lowered Henry Schein from a “hold” rating to a “sell” rating in a research note on Monday, August 8th. Bank of America Corp. started coverage on Henry Schein in a research note on Monday, September 12th. They set a “buy” rating and a $185.00 price objective on the stock. Finally, Robert W. Baird restated an “outperform” rating and set a $176.00 price objective (up previously from $175.00) on shares of Henry Schein in a research note on Tuesday, October 4th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Henry Schein currently has an average rating of “Buy” and a consensus price target of $157.92.
Shares of Henry Schein (NASDAQ:HSIC) opened at 163.04 on Tuesday. The firm has a 50-day moving average of $162.66 and a 200 day moving average of $170.44. Henry Schein has a 52-week low of $140.11 and a 52-week high of $183.00. The stock has a market capitalization of $13.34 billion, a PE ratio of 27.62 and a beta of 1.05.
Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Thursday, August 4th. The company reported $1.64 EPS for the quarter, beating the consensus estimate of $1.63 by $0.01. Henry Schein had a return on equity of 17.84% and a net margin of 4.42%. The firm earned $2.87 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same period in the prior year, the firm posted $1.46 earnings per share. The business’s quarterly revenue was up 9.3% compared to the same quarter last year. Equities research analysts forecast that Henry Schein will post $6.57 EPS for the current fiscal year.
In related news, Director Paul Brons sold 3,381 shares of the company’s stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $164.03, for a total value of $554,585.43. Following the transaction, the director now owns 13,715 shares in the company, valued at $2,249,671.45. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.27% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Quadrant Capital Group LLC boosted its stake in shares of Henry Schein by 0.4% in the second quarter. Quadrant Capital Group LLC now owns 742 shares of the company’s stock worth $128,000 after buying an additional 3 shares during the last quarter. Montag & Caldwell LLC boosted its position in Henry Schein by 0.3% in the second quarter. Montag & Caldwell LLC now owns 2,700 shares of the company’s stock valued at $477,000 after buying an additional 7 shares during the last quarter. Cleararc Capital Inc. boosted its position in Henry Schein by 0.9% in the second quarter. Cleararc Capital Inc. now owns 2,013 shares of the company’s stock valued at $356,000 after buying an additional 17 shares during the last quarter. Wetherby Asset Management Inc. boosted its position in Henry Schein by 0.6% in the second quarter. Wetherby Asset Management Inc. now owns 3,350 shares of the company’s stock valued at $592,000 after buying an additional 20 shares during the last quarter. Finally, Ranger Investment Management L.P. boosted its position in Henry Schein by 1.5% in the second quarter. Ranger Investment Management L.P. now owns 1,370 shares of the company’s stock valued at $242,000 after buying an additional 20 shares during the last quarter. Institutional investors and hedge funds own 91.98% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.
Receive News & Stock Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related stocks with our FREE daily email newsletter.